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Abstract
Background: IgA nephropathy (IgAN) and nephritis in Systemic Lupus Erythematosus (SLE) are two common forms of
glomerulonephritis in which genetic findings are of importance for disease development. We have recently reported an
association of IgAN with variants of TGFB1. In several autoimmune diseases, particularly in SLE, IRF5, STAT4 genes and TRAF1-
C5 locus have been shown to be important candidate genes. The aim of this study was to compare genetic variants from the
TGFB1, IRF5, STAT4 genes and TRAF1-C5 locus with susceptibility to IgAN and lupus nephritis in two Swedish cohorts.
Patients and Methods: We genotyped 13 single nucleotide polymorphisms (SNPs) in four genetic loci in 1252 DNA samples
from patients with biopsy proven IgAN or with SLE (with and without nephritis) and healthy age- and sex-matched controls
from the same population in Sweden.
Results: Genotype and allelic frequencies for SNPs from selected genes did not differ significantly between lupus nephritis
patients and SLE patients without nephritis. In addition, haplotype analysis for seven selected SNPs did not reveal a
difference for the SLE patient groups with and without nephritis. Moreover, none of these SPNs showed a significant
difference between IgAN patients and healthy controls. IRF5 and STAT4 variants remained significantly different between
SLE cases and healthy controls. In addition, the data did not show an association of TRAF1-C5 polymorphism with
susceptibility to SLE in this Swedish population.
Conclusion: Our data do not support an overlap in genetic susceptibility between patients with IgAN or SLE and reveal no
specific importance of SLE associated SNPs for the presence of lupus nephritis.
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Introduction
Several common gene variations have recently been shown to
associate with different autoimmune diseases, particularly System-
ic Lupus Erythematosus (SLE). Some nucleotide polymorphisms
(SNPs) have been shown to associate with single autoimmune
disease, while other SNPs associate with several diseases.
Interferon regulatory factor 5 (IRF5) polymorphism has been
shown to be a risk factor for the development of SLE [1,2,3,4,5],
rheumatoid arthritis (RA) [6,7,8,9], multiple sclerosis (MS) [10],
Sjo¨gren’s syndrome [11] and inflammatory bowel disease [12].
Signal transducers and activator of transcription 4 (STAT4) and
TNF receptor-associated factor 1-Complement component 5
(TRAF1-C5) polymorphisms have been found to associate with
both SLE and RA [13,14,15,16]. Recently we reported that
transforming growth factor-b1 (TGFB1), an important cytokine
gene, is in association with IgA nephropathy (IgAN) [17].
Immunological and biochemical similarities between SLE and
IgAN demonstrate a direct link to impaired immune function in
both diseases [18]. Patients with lupus nephritis and IgAN both
have circulating immune complexes and display anti-C1q
antibodies, which might point to certain pathogenic similarities
in these glomerular disorders [18,19]. Moreover, lupus nephritis
and IgAN are both chronic renal diseases that are classified in the
‘‘predominant’’ inflammatory group, based on morphological
similarities [20,21]. We hypothesized that it may be an overlap in
genetic susceptibility between lupus nephritis and IgAN and that
there could be specific genetic makers associated to the
development of nephritis in SLE patients.
To test this hypothesis we compared the genotype, allelic and
haplotype frequencies from IRF5, STAT4 and TRAF1-C5
polymorphisms between IgAN patients and healthy controls, and
SLE patients with and without nephritis, from TGFB1 polymor-
phisms between SLE patients and healthy controls.
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Materials and Methods
Patients and healthy subjects
Two cohorts of patients with SLE or IgAN, altogether 1252
individuals, were included in the present study. The cohort of
patients with SLE, consisted of 272 SLE patients, all self-reported
Caucasians from 18 to 80 years of age (mean age 45614 years).
106 SLE patients had biopsy proven nephritis (39%) and 166 SLE
patients had no clinical or laboratory signs of nephritis (61%). The
control group for SLE patients consisted of 307 healthy age-
matched individuals from the same population in Sweden, who
were 17 to 70 years old, mean age 44613 years.
In the IgAN cohort, there were altogether 673 DNA samples, of
which 196 samples were obtained from patients with biopsy-
proven IgAN, all self-reported Caucasians, and 477 samples were
collected from gender- and age matched healthy controls from the
same population in Sweden. Patients with Henoch-Scho¨nlein
purpura or with other forms of glomerulonephritis and individuals
with self-reported non-Caucasian ancestry were excluded in our
study. All patients gave written informed consent and the study
was approved by the Ethics Committee of the Karolinska
University Hospital, Stockholm, Sweden.
DNA extraction, selection of genetic markers, and
genotyping
DNA was extracted from EDTA blood samples (5–10 ml) by
the ‘‘salting out’’ method, as described elsewhere [22]. The SNPs
were selected because they had previously been shown to be
associated with SLE [5,14,15], RA [9,13,15], or with IgAN [17].
The SNPs were genotyped by fluorescent single base extension
using the multiplex SNPstream system (Beckman Coulter Inc) or
by TaqMan allelic discrimination assay (Applied Biosystems,
Foster City, U.S.A) (Table 1). All analyzed SNPs were in Hardy-
Weinberg equilibrium and the average positive rate of the
genotype detection was 97.2%. DNA samples with poor
performances in genotyping (,95% successful genotypes) were
excluded from the statistical evaluation.
Statistical analysis
To assess genotype, allele and haplotype frequencies, Pearson
Chi-square and/or Fisher’s Exact Tests were performed when
appropriate with PASWStatistics 18.0 Software. Haplotype
analysis was carried out by HaploView [23]. Power calculation
was performed for two-tail or one-tail tests when appropriate for
5% threshold of significance.
Results
IRF5, STAT4 and TRAF1-C5 polymorphisms did not show
an association with susceptibility and/or severity of IgAN
We did not find an association with disease susceptibility for the
investigated SNPs in IRF5, STAT4 genes and TRAF1-C5 locus, in
both the co-dominant model and the reccessive/dominant model,
comparing patients with IgAN and healthy controls. One IRF5
SNP (rs12539741) showed a difference between genotype
distribution in IgAN patients and healthy controls in males in
the dominant C model (p = 0.04). However, this association was
not significant after Bonferroni correction for multiple compari-
sons. Comparing the allele and haplotype frequencies, we did not
observe any significant differences for the SNPs between IgAN
patients and controls (Table 2).
TGFB1 polymorphisms did not show an association with
susceptibility to SLE or to lupus nephritis
No significant differences in genotype distribution or allele
frequencies were observed between SLE patients and healthy
controls for four investigated SNPs from the TGFB1 gene. In
addition, there was no significant difference between lupus
nephritis and healthy controls in both the co-dominant model
and the recessive/dominant model of genotype frequencies and
allelic frequencies (Table 3). TGFB1 polymorphisms in selected
SNPs did not show an association with SLE or with lupus nephritis
among SLE patients.
Genetic variations associated with susceptibility to SLE
did not correspond to a specific association with lupus
nephritis
To determine if SLE-related genetic variants associate specif-
ically with nephritis in SLE patients, we genotyped up to nine
variants from the IRF5, STAT4 genes and the TRAF1-C5 locus.
We compared genotype frequencies in both the co-dominant
Table 1. Polymorphisms of TGFB1, IRF5, STAT4 genes, TRAF1-C5 locus in the study.
Gene SNP Position Chromosome Chromosome position Alleles Methods
STAT4 rs10181656 Intron 3 2q32.2-q32.3 183829287 C/G TaqMan
IRF5 rs729302 Promoter 7q32 128356196 A/C SNPstream
IRF5 rs4728142 Promoter 7q32 128361203 A/G SNPstream
IRF5 rs2004640 The intron-exon border of exon 1B 7q32 128365537 G/T SNPstream
IRF5 rs3807306 Intron 1 7q32 128367916 G/T SNPstream
IRF5 rs10954213 39 UTR 7q32 128376663 A/G SNPstream
IRF5 rs11770589 Exon 10 39 UTR 7q32 128376724 A/G SNPstream
IRF5 rs2280714 39flanking region 7q32 128381961 C/T SNPstream
TRAF1-C5 rs3761847 59 flanking region 9q33-q34 93307696 A/G TaqMan
TGFB1 rs6957 Downstream 39genomic region 19q13.1 46522446 C/T TaqMan
TGFB1 rs2241715 Intron 1 19q13.1 46548726 G/T TaqMan
TGFB1 rs1982073 Signal sequence of exone 1 19q13.1 46550761 C/T TaqMan
TGFB1 rs1800469 Promoter 19q13.1 46552136 A/G TaqMan
doi:10.1371/journal.pone.0010559.t001
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model and recessive/dominant model between patients with lupus
nephritis and SLE patients without nephritis. We detected no
significant differences between these two groups. Moreover, there
were no significant differences in allele frequencies of any
investigated SNPs (Table 4). We found no differences in haplotype
analyses in patients with SLE and healthy controls or between
patients with lupus nephritis and SLE patients without nephritis.
Discussion
This is the first investigation to study the importance of IRF5,
STAT4 and TRAF1-C5 gene polymorphisms in patients with
IgAN. Our data show no evidence of an association of these genes
with the development of IgAN or distinct risk alleles for lupus
nephritis in this Swedish population.
According to recent findings, the IRF5 gene is an important
candidate gene in different chronic diseases, especially systemic
diseases related to inflammation and autoimmunity. A meta-
analysis which included 15 studies regarding IRF5 gene polymor-
phism and SLE, confirmed the importance of rs2004640 for SLE
susceptibility [4]. TRAF1-C5 and STAT4 polymorphisms have
been shown to associate with RA and SLE, and also with some
other autoimmune diseases [5,14,15].
Thus, one might speculate that susceptibility to IgA nephrop-
athy may be due to common variations in IRF5, TRAF1-C5 and
STAT4 genes. Our data do however not confirm this hypothesis.
Since no single marker (for IRF5, TRAF1-C5 and STAT4), no
haplotype associations (for IRF5) were detected in patients with
IgAN, it is reasonable to rule out a strong influence of these gene
polymorphisms in IgAN development or disease progression. We
noticed that we have almost 80% power to detect a 10% difference
in minor allele frequency (MAF) in our cases and controls.
However, due to limited sample size, we cannot exclude minor
influences from the investigated gene polymorphism on IgAN,
which may also differ in different populations. On the other hand,
TGFB1 polymorphisms were found previously in association with
the susceptibility to IgAN [17] but did not show any association
with SLE or lupus nephritis in the present study.
Table 2. Allelic frequencies of IRF5, STAT4 and TRAF1-C5 polymorphisms in IgAN patients and controls.
Gene SPNs Association Allele
Control/Patient
Ratio Counts Control/Patient Frequencies Chi Square P Value*
STAT4 rs10181656 A 532:388, 206:178 0.578, 0.769 1.927 0.2
IRF5 rs729302 A 629:299, 257:123 0.678, 0.676 0.003 0.9
IRF5 rs4728142 G 505:425, 206:176 0.543, 0.539 0.015 0.9
IRF5 rs2004640 G 444:486, 169:207 0.477, 0.449 0.840 0.4
IRF5 rs3807306 G 455:471, 177:201 0.491, 0.468 0.574 0.4
IRF5 rs10954213 G 342:584, 135:241 0.369, 0.359 0.122 0.7
IRF5 rs11770589 G 475:453, 193:191 0.512, 0.503 0.093 0.8
IRF5 rs2280714 C 294:636, 112:266 0.316, 0.296 0.494 0.5
TRAF1-C5 rs3761847 C 739:197, 297:89 0.790, 0.769 0.651 0.4
*Uncorrected.
doi:10.1371/journal.pone.0010559.t002
Table 3. Allelic frequencies of STAT4, IFR5, TRAF1-C5 and TGFB1 polymorphisms in SLE patients and controls.
Gene SPNs Association Allele
Control/Patient
Ratio Counts
Control/Patient
Frequencies Chi Square P Value*
STAT4 rs10181656 C 481:127, 343:201 0.791, 0.631 36.363 1.64E-09
IRF5 rs729302 C 124:248, 105:285 0.333, 0.269 3.722 0.0537
IRF5 rs4728142 G 206:166, 160:230 0.554, 0.410 15.708 7.39E-05
IRF5 rs2004640 G 181:191, 134:256 0.487, 0.344 16.048 6.17E-05
IRF5 rs3807306 G 177:195, 139:251 0.476, 0.356 11.182 8.00E-04
IRF5 rs10954213 G 131:241, 102:288 0.352, 0.262 7.364 0.0067
IRF5 rs11770589 A 195:177, 203:187 0.524, 0.521 0.01 0.9
IRF5 rs2280714 C 115:257, 87:303 0.309, 0.223 7.239 0.007
TRAF1-C5 rs3761847 A 334:258, 277:253 0.564, 0.523 1.946 0.2
TGFB1 rs6957 T 511:89, 453:91 0.852, 0.833 0.772 0.4
TGFB1 rs2241715 G 187:419, 164:378 0.309, 0.303 0.048 0.8
TGFB1 rs1982073 T 224:384, 198:344 0.368, 0.365 0.012 0.9
TGFB1 rs1800469 A 191:417, 162:378 0.314, 0.300 0.269 0.6
*Uncorrected.
doi:10.1371/journal.pone.0010559.t003
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There are immunological and biochemical similarities between
lupus nephritis and IgAN, and both conditions are associated with
immune complex formation and mesangial immune deposits.
There are also a number of reports on patients with SLE who
develop IgAN [24,25]. However, there was no overlap in genetic
risk factors in the here studied genes between SLE and IgAN
patients or any specific genetic variants detected comparing lupus
patients with or without nephritis.
An association of TRAF1-C5 locus with SLE was recently
detected in a relatively small cohort [14]. However, our data did
not show an association between TRAF1-C5 polymorphism
neither in SLE nor in IgAN.
In conclusion, the findings in the present study do not support
an overlap in genetic susceptibility between Swedish patients with
IgAN or SLE and reveal no specific importance of SLE associated
SNPs for presence of lupus nephritis.
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